<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05076032</url>
  </required_header>
  <id_info>
    <org_study_id>OXO-001-201</org_study_id>
    <secondary_id>2021-000001-25</secondary_id>
    <nct_id>NCT05076032</nct_id>
  </id_info>
  <brief_title>Phase II Clinical Trial to Evaluate the Ongoing Pregnancy Rate With OXO-001 in IVF/ICSI With Donor Oocytes.</brief_title>
  <acronym>OXOART2</acronym>
  <official_title>Phase II, Randomised, Double-blind, Parallel-group, Placebo-controlled Trial to Assess Ongoing Pregnancy Rate With OXO-001 (200/300 mg) or Placebo at 10 Weeks Following Fresh Single Blastocyst Transfer From Donor Oocyte IVF/ICSI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OXOLIFE</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OXOLIFE</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this clinical research trial is to test the efficacy of OXO-001 in a&#xD;
      daily oral administration increasing the pregnancy rate in IVF/ICSI by preparing the uterus&#xD;
      to receive the embryo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assisted reproductive techniques are the most common procedures to fulfill the desire for&#xD;
      pregnancy in infertile women. Unfortunately, more than half of the assisted reproduction&#xD;
      cycles result in implantation failure or early pregnancy loss, the two main causes of&#xD;
      infertility and the most important unmet medical need in the field of infertility with&#xD;
      current treatments.&#xD;
&#xD;
      This clinical trial aims to test the capacity of OXO-001 to enhance embryo implantation. It&#xD;
      is a phase II, randomised, double-blind, parallel-group, placebo-controlled trial that will&#xD;
      assess the ongoing pregnancy rate with OXO-001 (200 mg, 300 mg) or placebo at 10 weeks&#xD;
      following fresh single blastocyst transfer resulting from donor oocyte IVF/ICSI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A phase II, randomised, double-blind, parallel-group, placebo-controlled trial to assess the ongoing pregnancy rate with OXO-001 (200 mg, 300 mg) or placebo at 10 weeks following fresh single blastocyst transfer resulting from donor oocyte IVF/ICSI.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>10 weeks post Embryo Transfer (ET)</time_frame>
    <description>Rate of subjects with uterine pregnancy and a foetal heartbeat confirmed by ultrasound (US)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive blood pregnancy test</measure>
    <time_frame>10 to 15 days post ET</time_frame>
    <description>Percentage of women with positive blood pregnancy test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital pregnancy at 6 weeks</measure>
    <time_frame>6 weeks post ET</time_frame>
    <description>Intra-uterine pregnancy with foetal heartbeat at 6 weeks post ET</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early pregnancy loss rate</measure>
    <time_frame>10 weeks post ET</time_frame>
    <description>Early pregnancy loss rate within 10 weeks of gestation (i.e. after positive blood pregnancy test 10-15 days post ET).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From the first intake of the investigational product until 10 weeks post ET</time_frame>
    <description>Incidence and severity of adverse events/serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology and biochemistry values</measure>
    <time_frame>From the first intake of the investigational product until 10 weeks post ET</time_frame>
    <description>Changes from baseline in haematology and biochemistry values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>From the first intake of the investigational product until 10 weeks post ET</time_frame>
    <description>Changes from baseline in heart rate (bpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>From the first intake of the investigational product until 10 weeks post ET</time_frame>
    <description>Changes from baseline blood pressure mmHg</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">351</enrollment>
  <condition>Infertility, Female</condition>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>OXO-001 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two tablets of 100 mg have to be taken once daily in the early morning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OXO-001 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two tablets of 150 mg have to be taken once daily in the early morning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two tablets have to be taken once daily in the early morning.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OXO-001</intervention_name>
    <description>OXO-001 oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks approximately.</description>
    <arm_group_label>OXO-001 200 mg</arm_group_label>
    <arm_group_label>OXO-001 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks, approximately.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Voluntary informed consent.&#xD;
&#xD;
          -  Infertile female subjects indicated for egg donor programme in the context of ART.&#xD;
&#xD;
          -  Subjects aged ≥ 18 to ≤ 45 years at screening.&#xD;
&#xD;
          -  Body mass index (BMI) ≥ 18.0 and &lt; 30.0 kg/m2.&#xD;
&#xD;
          -  Normal results of a 2-dimensional (2D) or 3-dimensional (3D) transvaginal US (TVUS) at&#xD;
             screening.&#xD;
&#xD;
          -  Planned transfer of a fresh single blastocyst from a donated egg.&#xD;
&#xD;
          -  Good quality sperm.&#xD;
&#xD;
          -  Planned endometrial preparation and luteal support.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of two or more failed in-vitro fertilisation (IVF) / intra-cytoplasmic sperm&#xD;
             injection (ICSI) cycles after embryo transfer of donor oocyte during the last attempts&#xD;
             prior to the trial.&#xD;
&#xD;
          -  Gynaecological abnormality relevant to the ART procedure and outcome, which in the&#xD;
             opinion of the investigator could interfere with the trial objectives.&#xD;
&#xD;
          -  Abnormal haemorrhage of the reproductive tract of undetermined origin.&#xD;
&#xD;
          -  Endometrial biopsy or endometrial local injury within one month prior to screening.&#xD;
&#xD;
          -  Diagnosis of severe endometriosis and/or adenomyosis.&#xD;
&#xD;
          -  Positive hepatitis B surface antigen, hepatitis C virus antibody or human&#xD;
             immunodeficiency virus results.&#xD;
&#xD;
          -  Relevant clinically significant abnormality in the results of safety laboratory tests&#xD;
             at screening.&#xD;
&#xD;
          -  Systemic disease which might interfere with the purpose of the trial.&#xD;
&#xD;
          -  Any malignant neoplasm.&#xD;
&#xD;
          -  Known history of venous thrombosis or thromboembolism, including any coagulation&#xD;
             abnormality leading to an increased risk of clotting.&#xD;
&#xD;
          -  History of uncontrolled hypertension.&#xD;
&#xD;
          -  Known hypersensitivity to any component of the IP used in this trial.&#xD;
&#xD;
          -  Known allergy, hypersensitivity or any other contraindications to preparations used in&#xD;
             the context of endometrial preparation and fresh ET with a donated egg.&#xD;
&#xD;
          -  History (within 12 months) of or known current problems with alcohol or substance&#xD;
             abuse.&#xD;
&#xD;
          -  Any condition or treatment that, in the opinion of the investigator, may jeopardise&#xD;
             the trial conduct according to the protocol.&#xD;
&#xD;
          -  Previous treatment with the IP of this trial at any time or participation in another&#xD;
             clinical trial within the past 3 months prior to screening.&#xD;
&#xD;
          -  Employees of the investigator or trial centre, with direct involvement in the proposed&#xD;
             trial or other studies under the direction of that investigator or trial centre, as&#xD;
             well as family members of the employees or the principal investigator.&#xD;
&#xD;
          -  Persons committed to an institution by virtue of an order issued either by the&#xD;
             judicial or other authorities.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fertimed s.r.o.</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fertimed Olomouc</last_name>
      <phone>+420583551555</phone>
      <email>oxolife@oxolife.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ISCARE centrum asistované reprodukce</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ISCARE centrum asistované reprodukce Praha</last_name>
      <phone>800203233</phone>
      <email>oxolife@oxolife.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IVF CUBE</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>IVF CUBE Praha</last_name>
      <phone>+420 220 303 881</phone>
      <email>oxolife@oxolife.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanatorium PRONATAL</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanatorium PRONATAL Praha</last_name>
      <phone>+420 261 711 606</phone>
      <email>oxolife@oxolife.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UNICA Prague s.r.o</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>UNICA Prague Praha</last_name>
      <phone>+420 543 217 777</phone>
      <email>oxolife@oxolife.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pronatal NORD</name>
      <address>
        <city>Teplice</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pronatal NORD Teplice</last_name>
      <phone>+420 417 531 110</phone>
      <email>oxolife@oxolife.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika reprodukční medicíny a gynekologie</name>
      <address>
        <city>Zlín</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klinika reprodukční medicíny a gynekologie Zlín</last_name>
      <phone>+420 577 005 924</phone>
      <email>oxolife@oxolife.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Provita Sp. z o.o.</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Provita Katowice</last_name>
      <phone>48 32 783 73 00</phone>
      <email>oxolife@oxolife.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VitroLive Sp. z o.o.</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VitroLive Sp Szczecin</last_name>
      <phone>+48 91 486 43 45</phone>
      <email>oxolife@oxolife.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OVIklinika</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>OVIklinika Warszawa</last_name>
      <phone>+48 22 112 56 00</phone>
      <email>oxolife@oxolife.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Przychodnia Lekarska nOvum, Katarzyna Kozioł, Piotr Lewandowski spółka jawna</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Przychodnia Lekarska nOvum, Katarzyna Kozioł Warszawa</last_name>
      <phone>+48 22 566 80 00</phone>
      <email>oxolife@oxolife.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Bernabeu</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madrid Alicante</last_name>
      <phone>965 154 000</phone>
      <email>oxolife@oxolife.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Dexeus</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hospital Universitari Dexeus Barcelona</last_name>
      <phone>932 274 700</phone>
      <email>oxolife@oxolife.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quirónsalud Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hospital Universitario Quirónsalud Barcelona</last_name>
      <phone>93 255 40 00</phone>
      <email>oxolife@oxolife.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IVI Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>IVI Barcelona</last_name>
      <phone>932 063 000</phone>
      <email>oxolife@oxolife.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IVI Bilbao</name>
      <address>
        <city>Leioa</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>IVI Bilbao</last_name>
      <phone>944 806 020</phone>
      <email>oxolife@oxolife.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GINEFIV Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GINEFIV Madrid</last_name>
      <phone>900 908 988</phone>
      <email>oxolife@oxolife.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quirónsalud Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hospital Universitario Quirónsalud Madrid</last_name>
      <phone>902 024 747</phone>
      <email>oxolife@oxolife.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Bernabeu Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Instituto Bernabeu B Madrid</last_name>
      <phone>918 333 882</phone>
      <email>oxolife@oxolife.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IVI Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>IVI Madrid</last_name>
      <phone>915 633 881</phone>
      <email>oxolife@oxolife.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IVI Mallorca</name>
      <address>
        <city>Palma De Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>IVI Mallorca</last_name>
      <phone>971 286 663</phone>
      <email>oxolife@oxolife.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ginemed Sevilla</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ginemed Sevilla</last_name>
      <phone>954 991 051</phone>
      <email>oxolife@oxolife.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IVI Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>IVI Valencia</last_name>
      <phone>960 451 185</phone>
      <email>oxolife@oxolife.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IVI Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>IVI Zaragoza</last_name>
      <phone>900 847 300</phone>
      <email>oxolife@oxolife.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 21, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endometrial receptivity</keyword>
  <keyword>Embryo implantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

